Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 77Carcinoma, Non-Small-Cell Lung 64Lung Neoplasms 31Hodgkin Disease 13Lymphoma 11Neoplasm Metastasis 10Recurrence 8Lymphoma, Non-Hodgkin 8Prostatic Neoplasms 7Neoplasms 7Adenocarcinoma of Lung 7Uterine Cervical Neoplasms 5Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Mesothelioma, Malignant 4Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms, Male 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Burkitt Lymphoma 3Brain Neoplasms 3Waldenstrom Macroglobulinemia 2

Interventions

seribantumab 2zenocutuzumab 1patritumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lethal Congenital Contracture Syndrome 2 × Vinorelbine × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡